A plain-spoken reading desk for the tirzepatide literature — what the 2024-2025 trials actually found, walked through one step at a time.
Tirzepatide Order

About Tirzepatide Order: An Independent Research Digest

About this site

Tirzepatide Order is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide — the first FDA-approved dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain name 'Tirzepatide Order' is an editorial position relative to the literature — it describes our approach to the research record (systematic, stepped, walked through in the right order) — not a claim that this site offers, fulfills, or facilitates any prescription, sale, or order of any medicine. No medicine, product, or prescription service is available here.

This site focuses on the 2024-2025 trial literature as its primary lens. That means SURMOUNT-5 (the 2025 head-to-head), the body-composition DXA substudy, the physical-function meta-analysis, the SYNERGY-NASH and SUMMIT and SURPASS-CVOT readouts, and the 2025 pharmacovigilance and safety literature are the front door — with the foundational SURMOUNT-1, SURPASS-2, and mechanism literature following as context. Our goal is to give a curious, non-specialist reader a fair picture of what the clinical trial record actually shows — including the effect sizes, the confidence intervals, the adverse-event profile, and the genuine evidence gaps.

How we use citations

Every quantitative claim on this site cites a numbered reference in the Tirzepatide references page. Numbered inline citations [N] in the body text correspond to those references by ID. We draw exclusively from the peer-reviewed literature and regulatory documents (FDA labels, ClinicalTrials.gov registry entries). We do not invent citations, fabricate DOIs, or paraphrase a claim beyond what the cited paper supports.

The primary trial literature — SURMOUNT-1, SURMOUNT-5, SURPASS-2, and the supporting SURPASS and SURMOUNT programme papers — is cited at the New England Journal of Medicine, Lancet, JAMA, Nat Med, and Diabetes Obes Metab level. Safety analyses are cited from meta-analyses and pharmacovigilance sources, not from individual case reports. Mechanism claims are cited from the original receptor-pharmacology papers and recent reviews.

If you find a claim on this site that you believe is unsupported by its cited source, please contact us via the contact page.

What this site is not

This site is not a clinic, a pharmacy, a telehealth service, or a vendor. It does not sell, dispense, prescribe, or facilitate access to tirzepatide or any other medicine. 'Order' in the domain name refers to the editorial structure of this site, not a product transaction. If you are seeking medical care, prescription evaluation, or treatment for diabetes or obesity, those are conversations with a licensed healthcare provider — not with an editorial website. Tirzepatide is a prescription medicine requiring a clinician's evaluation and prescription; nothing on this site substitutes for that.